Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.
Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
E A
EA
Lasater
Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
E S
ES
Massi
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
A
A
Stecula
Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
J
J
Politi
Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
S K
SK
Tan
Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
C C
CC
Smith
Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
M
M
Gunthorpe
Annadel Medical Group, Santa Rosa, CA, USA.
J P
JP
Holmes
Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
F
F
Chehab
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.|Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.|California Institute for Quantitative Biosciences, University of California, San Francisco, CA, USA.
A
A
Sali
Division of Hematology/Oncology, University of California, San Francisco, CA, USA.|Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
N P
NP
Shah
D000077784:Axitinib; D000069439:Dasatinib / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D007191:Indazoles / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011724:Pyridazines / Q000627:therapeutic use
D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D000077784:Axitinib; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib